Swiss Pharma's Global Success Meets Worries At Home

(MENAFN- Swissinfo) When Switzerland's two biggest pharmaceutical companies are doing well, that's usually a reason to celebrate. Swissinfo journalist Jessica Davis Plüss examines why Swiss politicians and industry leaders are instead calling for urgent reforms to keep the country attractive to pharma. This content was published on February 13, 2026 - 09:00 8 minutes

I report on the Swiss pharmaceutical industry and healthcare topics such as access to medicine, biomedical innovation, and the impact of diseases like cancer. I grew up just outside San Francisco and studied international affairs with a focus on development economics and healthcare policy. Prior to joining SWI swissinfo in 2018, I was a freelance journalist and a researcher on business and human rights.

• More from this aut
• English Departm

Last year was a good year for Swiss pharma. Roche's sales rose 7% (at constant exchange rates) to CHF61.5 billion ($79.8 billion), driven by strong demand for drugs for multiple sclerosis, eye diseases and Haemophilia A. With ten new molecules entering late-stage clinical trials, 2025 was“very much a record year for Roche”, said CEO Thomas Schinecker at the company's annual results media conference in January.

Its cross-town rival, Novartis, was also upbeat about 2025, with sales of key brands“well above expectations”, according to its annual reportExternal link, enough to boost CEO Vas Narasimhan's compensation by 30%. Even with generic competition expected to dent sales in 2026, Novartis' US shares were trading at all-time highs in early February.

They are now the two most valuable companies in Switzerland, according to a global ranking by consulting firmExternal link EY. Roche rose to 31st from 46th with a market capitalisation of $353.4 billion, up more than 50% on the previous year. Novartis rose from 66th to 53rd with $265.2 billion, replacing food giant Nestlé as the second-most valuable Swiss company.

One would assume all this good news for Switzerland's largest companies would be good news for Switzerland. The two companies are among the country's biggest taxpayers, employ some 25,000 people in the country and support thousands of jobs indirectly.

The biopharma industry as a whole, which includes thousands of smaller companies, was responsibleExternal link for 40% of the country's economic growth over the last decade. It generates around 7% of GDP, and over 40% of Swiss exports, making it the most important export sector.

But instead of celebration, Swiss politicians and industry leaders are racing to enact what they see as urgent reforms to retain Switzerland's reputation as a pharma powerhouse.

More More Healthcare innovation US trade deal forces reckoning for Swiss pharma powerhouse

This content was published on Nov 18, 2025 Swiss pharma made massive investment promises to the US that are fueling anxiety about the industry's future in Switzerland.

Read more: US trade deal forces reckoning for Swiss pharma power

MENAFN13022026000210011054ID1110738440